Liver-directed therapies for metastatic neuroendocrine tumors
Liver-directed therapies for metastatic neuroendocrine tumors
复制标题
DOI：
10.1016/j.hoc.2007.04.003
复制
发表时间：
2007-06-01
影响因子：
2.4
通讯作者：
Stuart, Keith
中科院分区：
文献类型：
--
作者：
Garrot, Crain;Stuart, Keith
神经内分泌肿瘤尽管是惰性的，但经常因肝转移病变而导致显着的发病率和死亡率。可以通过栓塞/化疗栓塞、射频消融或其他疗法直接针对这些肝脏病变。现有的观察性研究似乎表明生存期有所延长。肝脏定向治疗也能够减轻大多数患者的症状。因此，这些治疗干预措施的价值主要在于其姑息能力。结合奥曲肽的积极使用，局部消融技术通常可以控制激素过量和肿瘤体积的症状。然而，由于这些干预措施可能产生不利影响，因此必须仔细选择患者，以尽量减少手术的发病率和死亡率。
Neuroendocrine tumors, despite being indolent, frequently cause significant morbidity and mortality from hepatic metastatic lesions. It is possible to directly target these liver lesions with embolization/chemoembofization, radiofrequency ablation, or other therapies. The observational studies that exist seem to indicate a prolongation of survival. Liver-directed therapies are also able to decrease symptoms in most patients. The value of these therapeutic interventions therefore lies mainly in their palliative capabilities. Coupled with aggressive use of octreotide, local ablative techniques may frequently control symptoms of hormone excess and tumor bulk. Because of the possible adverse effects of these interventions, however, careful patient selection is essential to minimize the morbidity and mortality of the procedures.